Évaluation oncogériatrique du sujet âgé ayant un cancer urologique métastatique

25 novembre 2008

Auteurs : Y. Neuzillet, A. Méjean, T. Lebret
Référence : Prog Urol, 2008, 18, S415, suppl. S7
   
 
 

 

 
Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser

   

 

 
 
 

Références

 

Rochon P.A., Katz J.N., Morrow L.A., McGlinchey-Berroth R., Ahlquist M.M., Sarkarati M., Minaker K.L. Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability A prospective comparison of three comorbidity indices Med Care 1996 ;  34 : 1093-1101 [cross-ref]
 
Feinstein A.R. The pre-therapeutic classification of co-morbidity in chronic disease J Chronic Dis 1970 ;  23 : 455-468 [cross-ref]
 
Fontaine K.R., Redden D.T., Wang C., Westfall A.O., Allison D.B. Years of life lost due to obesity JAMA 2003 ;  289 : 187-193 [cross-ref]
 
Seve P., Sawyer M., Hanson J., Broussolle C., Dumontet C., Mackey J.R. The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a populationbased study Cancer 2006 ;  106 : 2058-2066 [cross-ref]
 
Chester J.D., Hall G.H., Forster M., Protheroe A.S. Systemic chemotherapy for patients with bladder cancer - current controversies and future directions Cancer Treat Rev 2004 ;  30 : 343-358 [cross-ref]
 
De Groot V., Beckerman H., Lankhorst G.J., Bouter L.M. How to measure comorbidity. A critical review of available methods J Clin Epidemiol 2003 ;  56 : 221-229 [cross-ref]
 
Linn B.S., Linn M.W., Gurel L. Cumulative illness rating scale J Am Geriatr Soc 1968 ;  16 : 622-626 [cross-ref]
 
Hudon C., Fortin M., Vanasse A. Cumulative Illness Rating Scale was a reliable and valid index in a family practice context J Clin Epidemiol 2005 ;  58 : 603-608 [cross-ref]
 
Nagaratnam N., Gayagay G. Validation of the Cumulative Illness Rating Scale (CIRS) in hospitalized nonagenarians Arch Gerontol Geriatr 2007 ;  44 : 29-36 [cross-ref]
 
Parmelee P.A., Thuras P.D., Katz I.R., Lawton M.P. Validation of the Cumulative Illness Rating Scale in a geriatric residential population J Am Geriatr Soc 1995 ;  43 : 130-137 [cross-ref]
 
Kaplan M.H., Feinstein A.R. The importance of classifying initial co-morbidity in evaluatin the outcome of diabetes mellitus J Chronic Dis 1974 ;  27 : 387-404 [cross-ref]
 
Charlson M.E., Pompei P., Ales K.L., Mackenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 1987 ;  40 : 373-383 [cross-ref]
 
Buntinx F., Niclaes L., Suetens C., Jans B., Mertens R., van den Akker M. Evaluation of Charlson’s comorbidity index in elderly living in nursing homes J Clin Epidemiol 2002 ;  55 : 1144-1147 [cross-ref]
 
Harboun M., Ankri J. Indices de comorbidité : revue de la littérature et application aux études des populations âgées Rev Epidemiol Sante Publique 2001 ;  49 : 287-298 [inter-ref]
 
Greenfield S., Apolone G., McNeil B.J., Cleary P.D. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement Comorbidity and outcomes after hip replacement Med Care 1993 ;  31 : 141-154 [cross-ref]
 
Stier D.M., Greenfield S., Lubeck D.P., Dukes K.A., Flanders S.C., Henning J.M., Weir J., Kaplan S.H. Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer Urology 1999 ;  54 : 424-429 [inter-ref]
 
Litwin M.S., Greenfield S., Elkin E.P., Lubeck D.P., Broering J.M., Kaplan S.H. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice Cancer 2007 ;  109 : 1777-1783 [cross-ref]
 
Extermann M. Measuring comorbidity in older cancer patients Eur J Cancer 2000 ;  36 : 453-471 [cross-ref]
 
Hall W.H., Jani A.B., Ryu J.K., et al. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer Prostate Cancer Prostatic Dis 2005 ;  8 : 22-30 [cross-ref]
 
Singh R., O’Brien T.S. Comorbidity assessment in localized prostate cancer: a review of currently available techniques Eur Urol 2004 ;  46 : 28-41 [cross-ref]
 
Albertsen P.C., Fryback D.G., Storer B.E., Kolon T.F., Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer J Urol 1996 ;  156 : 127-132 [cross-ref]
 
Imamura K., McKinnon M., Middleton R., Black N. Reliability of a comorbidity measure: the Index of Co-Existent Disease (ICED) J Clin Epidemiol 1997 ;  50 : 1011-1016 [cross-ref]
 
Boulos D.L., Groome P.A., Brundage M.D., Siemens D.R., Mackillop W.J., Heaton J.P., Schulze K.M., Rohland S.L. Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent Cancer 2006 ;  106 : 1804-1814 [cross-ref]
 
LU-Yao G., Moore D.F., Oleynick J.U., Dipaola R.S., Yao S.L. Population based study of hormonal therapy and survival in men with metastatic prostate cancer J Urol 2007 ;  177 : 535-539 [cross-ref]
 
Négrier S., Escudier B., Gomez F., Douillard J.Y., Ravaud A., Chevreau C., Buclon M., Pérol D., Lasset C. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie Ann Oncol 2002 ;  13 : 1460-1468
 
Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 1999 ;  17 : 2530-2540
 
Motzer R.J., Bacik J., Murphy B.A., Russo P., Mazumdar M. Interferon- alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 2002 ;  20 : 289-296 [cross-ref]
 
Motzer R.J., Bacik J., Schwartz L.H., Reuter V., Russo P., Marion S., Mazumdar M. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma J Clin Oncol 2004 ;  22 : 454-463 [cross-ref]
 
Saxman S.B., Propert K.J., Einhorn L.H., Crawford E.D., Tannock I., Raghavan D., Loehrer P.J.S.R., Trump D. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J Clin Oncol 1997 ;  15 : 2564-2569 [cross-ref]
 
von der Maase H., Sengelov L., Roberts J.T., Ricci S., Dogliotti L., Oliver T., Moore M.J., Zimmermann A., Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 2005 ;  23 : 4602-4608 [cross-ref]
 
Dodd P.M., McCaffrey J.A., Herr H., Mazumdar M., Bacik J., Higgins G., Boyle M.G., Scher H.I., Bajorin D.F. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma J Clin Oncol 1999 ;  17 : 2546-2552
 
Saklad M. Grading of patients for surgical procedures Anesthesiology 1941 ;  2 : 281-284 [cross-ref]
 
Froehner M., Koch R., Litz R., Heller A., Oehlschlaeger S., Wirth M.P. Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy Urology 2003 ;  62 : 698-701 [inter-ref]
 
Extermann M., Overcash J., Lyman G.H., Parr J., Balducci L. Comorbidity and functional status are independent in older cancer patients J Clin Oncol 1998 ;  16 : 1582-1587 [cross-ref]
 
Cohen H.J., Feussner J.R., Weinberger M., et al. A controlled trial of inpatient and outpatient geriatric evaluation and management N Engl J Med 2002 ;  346 : 905-912 [cross-ref]
 
Balducci L., Yates J. General guidelines for the management of older patients with cancer Oncology (Williston Park) 2000 ;  14 : 221-227
 
Balducci L., Extermann M. Management of cancer in the older person: a practical approach Oncologist 2000 ;  5 : 224-237 [cross-ref]
 
Droz J.P., Chaladaj A. Management of metastatic prostate cancer: the crucial role of geriatric assessment BJU Int 2008 ;  101 : 23-29 [cross-ref]
 
Balducci L., Cox C.E., Greenberg H., Miguel R.V., Karl R., Fabri P.J. Management of Cancer in the Older Aged Person Cancer Control 1994 ;  1 : 132-137
 
Terret C., Albrand G., Droz J.P. Geriatric assessment in elderly patients with prostate cancer Clin Prostate Cancer 2004 ;  2 : 236-240 [cross-ref]
 
Miller D.K., Lewis L.M., Nork M.J., Morley J.E. Controlled trial of a geriatric case-finding and liaison service in an emergency department J Am Geriatr Soc 1996 ;  44 : 513-520 [cross-ref]
 
Fletcher A.E., Price G.M., Ng E.S., et al. Population-based multidimensional assessment of older people in UK general practice: a cluster-randomised factorial trial Lancet 2004 ;  364 : 1667-1677 [cross-ref]
 
Stuck A.E., Egger M., Hammer A., Minder C.E., Beck J.C. Home visits to prevent nursing home admission and functional decline in elderly people: systematic review and meta-regression analysis JAMA 2002 ;  287 : 1022-1028 [cross-ref]
 
Fried L.P., Tangen C.M., Walston J., et al. Cardiovascular Health Study Collaborative Research Group Frailty in older adults: evidence for a phenotype J Gerontol A Biol Sci Med Sci 2001 ;  56 (3) : 146-156
 
Folsom A.R., Jacobs D.R., Caspersen C.J., Gomez-Marin O., Knudsen J. Test-retest reliability of the Minnesota Leisure Time Physical Activity Questionnaire J Chronic Dis 1986 ;  39 : 505-511 [cross-ref]
 
Lee S.J., Lindquist K., Segal M.R., Covinsky K.E. Development and validation of a prognostic index for 4-year mortality in older adults Development and validation of a prognostic index for 4-year mortality in older adults JAMA 2006 ;  295 (7) : 801-808 [cross-ref]
 
   
 
 
   

 

© 2008  Elsevier Masson SAS. Tous droits réservés.